23 completed, 4 terminated, 3 recruiting, 2 withdrawn. 34 Phase 2, 5 Phase 1, 4 Phase 3.
Follow matched placebo: new trials by email Literature Review of matched placebo trials Research Report on matched placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI) JUV-161, Placebo - Healthy Volunteers | Phase 1 / Phase 2 | Recruiting | Juvena Therapeutics | 36 | 2026-02-28 | 2026-04-20 |
| Glucokinase Activator in Monogenic Diabetes Dorzagliatin, matched placebo - Diabetes Mellitus, Monogenic Diabetes | Phase 2 | Recruiting | Chinese University of Hong Kong | 44 | 2025-04-30 | 2026-04-30 |
| A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer HB-202/HB-201 alternating 2-vector therapy, Placebo, Pembrolizumab - Oropharyngeal Squamous Cell Carcinoma Recurrent | Phase 2 / Phase 3 | Withdrawn | Hookipa Biotech GmbH | 2024-12-01 | 2025-06-22 | |
| Efficacy and Safety of HB-1 for Panic Disorder HB-1, Telmisartan Only Product in Oral Dose Form, Verapamil Only Product in Oral Dose Form - Panic Disorder, Mental Illness | Phase 2 | Terminated | HB BioTech, LLC | 170 | 2024-10-29 | 2026-09-24 |
| A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD). NST-6179 Part A, NST-6179 Part B, Matched Placebo - Intestinal Failure Associated Liver Disease | Phase 2 | Recruiting | NorthSea Therapeutics B.V. | 36 | 2024-01-15 | 2025-01-07 |
| Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression NV-5138, matched placebo - Treatment Resistant Depression | Phase 2 | Completed | Navitor Pharmaceuticals, Inc. | 250 | 2022-01-18 | 2026-04-17 |
| Development of a Selective ALDH2 Inhibitor to Treat AUD ANS-6637 Low Dose, ANS-6637 High Dose, Matched Placebo - Alcohol Use Disorder | Phase 2 | Withdrawn | University of California, Los Angeles | 2020-04-01 | 2021-05-25 | |
| Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock nangibotide low dose, nangibotide high dose, placebo - Shock, Septic | Phase 2 | Active not recruiting | Inotrem | 355 | 2019-11-13 | 2023-04-11 |
| Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection XF-73, Placebo - Staphylococcal Infections, Surgical Site Infection | Phase 2 | Completed | Destiny Pharma Plc | 124 | 2019-08-29 | 2023-10-16 |
| Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) Cannabidivarin, Matched Placebo - Autism Spectrum Disorder | Phase 2 | Completed | Montefiore Medical Center | 50 | 2019-04-12 | 2026-11-06 |
| Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome Intranasal Oxytocin (IN-OXT), Matched Placebo - Prader-Willi Syndrome, Hyperphagia | Phase 2 | Completed | Eric Hollander | 32 | 2018-04-11 | 2025-02-07 |
| A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis IVA, TEZ/IVA, VX-445 - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 225 | 2017-01-23 | 2022-01-18 |
| Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients Clonazepam, Placebo - Cannabis Use Disorder | Phase 2 | Completed | New York State Psychiatric Institute | 68 | 2016-12-01 | 2021-08-06 |
| A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis TEZ, IVA, VX-440 - Cystic Fibrosis | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 74 | 2016-10-01 | 2020-08-28 |
| Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder Adderall-XR, Matched placebo - Cannabis Use Disorder, Attention-deficit/Hyperactivity Disorder | Phase 2 / Phase 3 | Completed | New York State Psychiatric Institute | 33 | 2016-07-01 | 2021-04-09 |
| Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children Influenza virus vaccine, Vitamins A and D, Placebo - Healthy Participants | Phase 2 | Completed | St. Jude Children's Research Hospital | 87 | 2016-01-21 | 2019-10-29 |
| Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome Intranasal Oxytocin (IN-OXT), Matched Placebo - Prader-Willi Syndrome, Hyperphagia | Phase 2 | Completed | Montefiore Medical Center | 23 | 2015-10-01 | 2021-10-07 |
| The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program Melatonin, Matched Placebo - Substance Withdrawal Syndrome | Phase 1 / Phase 2 | Completed | Duquesne University | 70 | 2015-05-01 | 2016-08-08 |
| Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus Part A: Placebo, Part A: CR845 0.5 mcg/kg, Part A: CR845 1.0 mcg/kg - Pruritus, Uremic Pruritus | Phase 2 | Completed | Cara Therapeutics, Inc. | 89 | 2014-07-01 | 2016-08-10 |
| Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF) Omeprazole, Matched placebo - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Newcastle-upon-Tyne Hospitals NHS Trust | 45 | 2014-03-28 | 2017-11-20 |
Showing 20 of 34. Sign in to see all of them.
Cystic Fibrosis (2) · Head and Neck Neoplasms (2) · Hyperphagia (2) · Marijuana Abuse (2) · Prader-Willi Syndrome (2) · Alcoholism (1) · Anxiety Disorders (1) · Asthma (1) · Attention Deficit Disorder with Hyperactivity (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Cocaine-Related Disorders (1) · Colitis, Ulcerative (1) · Depression (1) · Depressive Disorder, Treatment-Resistant (1)
New York State Psychiatric Institute (3) · Khon Kaen University (2) · Montefiore Medical Center (2) · Vertex Pharmaceuticals Incorporated (2) · Abbott (1) · Cara Therapeutics, Inc. (1) · Chinese University of Hong Kong (1) · Destiny Pharma Plc (1) · Duquesne University (1) · Eric Hollander (1) · GlaxoSmithKline (1) · HB BioTech, LLC (1) · Heather Patton (1) · Hookipa Biotech GmbH (1) · Inotrem (1)
United States (20) · United Kingdom (5) · Australia (4) · Belgium (4) · Spain (4) · Canada (3) · Denmark (2) · France (2) · Germany (2) · Netherlands (2) · Thailand (2) · Austria (1) · Finland (1) · Georgia (1) · Hong Kong (1)
Eric Hollander, MD (3) · Brian H Annex, MD (1) · Charles H. Kellner, M.D. (1) · Chris Brett, MD (1) · Erica Grodin, PhD (1) · Frances R Levin, MD (1) · Frederique Menzaghi, PhD (1) · Heather M Patton, MD (1) · Iain McNeish (1) · Ian Forrest, MRCP (1) · Jean-Jacques Garaud, MD (1) · Jesus M Gonzalez Moreno, MD (1) · Jim P Lees, BSc (1)
PMID 21473764, PMID 24684534, PMID 24911028, PMID 25070546, PMID 25209738, PMID 30334692, PMID 33331662, PMID 34233965, PMID 36951472, PMID 37269870, PMID 37983082, PMID 39402448, PMID 40656115
U54DA037842 (2), 2009 (1), 2016 (1), 2017 (1), 2018 (1), R01DA031826 (1), R21AT000939 (1), U10DA013732 (1)